Skip to content
The Nexus
DossierENTITY

Dr. Mark Goldsmith

Coverage of Dr. Mark Goldsmith in the Nexus archive.

Earliest in view: Jun 4 · 08:48 UTCMost recent: Jun 5 · 12:30 UTC
Co-mentioned in this coverage
pancreatic cancertopic2Revolution Medicinesorganization2biotech companyorganization1chemotherapytopic1Isobel Yeungperson1Hezbollahorganization1Jasmine Garsdperson1Aaron Recihlin-Melinkperson1NPRorganization1Delaney Hall detention centerplace1daraxonrasibtopic1Redwood Cityplace1FDAorganization1
Recent coverage
  • HEALTHJun 5 · 12:30 UTCCROSSCUT SEATTLE
    A New Pill Finally Offers Hope for Pancreatic Cancer

    A new daily pill for pancreatic cancer has shown to reduce the risk of death by 60% compared to chemotherapy in a study involving 500 patients. The drug, developed by a biotech company, is doubling survival time for patients with an aggressive form of the disease.

  • SECURITYJun 5 · 12:15 UTCCROSSCUT SEATTLE
    June 4, 2026

    Correspondent Isobel Yeung reports on Hezbollah's grip on power. NPR's Jasmine Garsd and Aaron Recihlin-Melink analyze protests at Delaney Hall detention center. Dr. Mark Goldsmith discusses a pancreatic cancer treatment breakthrough.

  • HEALTHJun 4 · 08:48 UTCNBC BAY AREA
    Redwood City company develops pill to treat pancreatic cancer, and trial results are promising

    A Redwood City company, Revolution Medicines, developed an experimental pill called daraxonrasib for pancreatic cancer, showing trial results that doubled patient survival rates from six and a half months to over 13 months compared to chemotherapy. The drug is now being fast-tracked by the FDA.

Dr. Mark Goldsmith · Dossier · The Nexus